Shilpa Medicare Limited’s subsidiary, Shilpa Pharma Lifesciences Limited, has received a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & Healthcare (EDQM) for its Active Pharmaceutical Ingredient (API), Desmopressin.
Desmopressin, a synthetic peptide produced by Shilpa Pharma through solid-phase synthesis, is used to treat central diabetes insipidus and bedwetting by reducing frequent urination and excessive thirst. This marks a significant milestone as Desmopressin is the first peptide molecule from Shilpa Pharma to receive a CEP from European regulators.
Mr. Keshav Bhutada, Executive Director of Shilpa Pharma Lifesciences, expressed that the CEP is a testament to the company’s commitment to quality-oriented development and manufacturing capabilities that align with global standards. He also indicated that this achievement sets the stage for the company to develop more peptide products.
The recognition is part of Shilpa’s ongoing investment in expanding its peptide portfolio and developing high-quality pharmaceutical products to meet global standards.
